Positive outcome confirms efficacy of MabThera in moderate-severe rheumatoid arthritis03 nov 2004
Roche
Roche together with development partners Genentech and Biogen Idec announced today that a Phase IIb clinical study of MabThera/Rituxan (rituximab) met its primary endpoint of a greater proportion ...